Skip to content
NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · SMALL CAP

OmniAb, Inc. OABI

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$18.7M
▼ 29.3% YoY
$-64.8M
$-37.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We believe the OmniAb animals comprise the most diverse host systems available in the industry. As of December 31, 2025, we had 107 active partners with 407 active programs using the OmniAb technology platform, including 27 OmniAb-derived antibodies in clinical development by our partners, two under regulatory review, and three approved products developed and commercialized by our partners. Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. As part of our efforts to enhance the partner experience, we launched OmniHub™ in December 2024.

Written from the business description in OmniAb, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 4 March 2026. Every sentence was checked against that document before publication.

Growth

USD 18.7M
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 18.7 · Net income -64.8
25.0M50.0M-25.0M-50.0M
202120242025
Compound annual growth
−31.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−347 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -369.5% · Net -347.0%
-100%-200%-300%
202120232025
ROE
FY2025 · ROE -23.4%
-10%-20%
202120232025
Three returns, three denominators.

Each USD of equity lost 23 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -37.0
-15M-30M
202120232025

Total assetsUSD 300.9M
EquityUSD 267.0M
CashUSD 25.5M
Current ratio4.02×

Equity funds 89% of total assets.

The 5-year record

5 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
OABI, 5-year financial record
Metric 20252024202320222021
Revenue $B0.00.00.00.10.0
Operating income $B−0.1−0.1−0.1−0.0−0.0
EBITDA $B−0.0−0.1−0.0−0.0−0.0
Income tax $B−0.0−0.0−0.0−0.0−0.0
Net income $B−0.1−0.1−0.1−0.0−0.0
Free cash flow $B−0.0−0.00.0−0.0−0.0
EPS, diluted $−0.57−0.61−0.51−0.26−0.33
Dividend / sh $◌◌◌◌◌
Payout % — not applicable: no dividend—————
ROE %−23.4−20.6−15.4−7.8−11.5
Shares out B0.140.120.120.120.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 21 reconciliationsAUDITED

Reconciled in 5 of the 5 fiscal years we could check. 28 checks were skipped: the balance sheet is not tagged before 2021. 14 checks were skipped: EPS is not tagged before 2021.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Commercial Physical & Biological Research
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2007

Share this section

Download image